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Abstract 
Dystrobrevin binding protein 1 (DTNBP1), or dysbindin, is thought to be critical in 
regulating the glutamatergic system.  While the dopamine pathway is known to be 
important in the aetiology of schizophrenia, it seems likely that glutamatergic 
dysfunction can lead to the development of schizophrenia.  DTNBP1 is widely 
expressed in brain, levels are reduced in brains of schizophrenia patients and a 
DTNBP1 polymorphism has been associated with reduced brain expression.  Despite 
numerous genetic studies no DTNBP1 polymorphism has been strongly implicated in 
schizophrenia aetiology.  Using a haplotype block-based gene-tagging approach we 
genotyped 13 single nucleotide polymorphisms (SNPs) in DTNBP1 to investigate 
possible associations with DTNBP1 and schizophrenia.  Four polymorphisms were 
found to be significantly associated with schizophrenia.  The strongest association 
was found with an A/C SNP in intron seven (rs9370822).  Homozygotes for the C-
allele of rs9370822 were more than two and a half times as likely to have 
schizophrenia compared to controls.  The other polymorphisms showed much weaker 
association and are less likely to be biologically significant.  These results suggest that 
DTNBP1 is a good candidate for schizophrenia risk and rs9370822 is either 
functionally important or in disequilibrium with a functional SNP, although our 
observations should be viewed with caution until they are independently replicated. 
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1.  Introduction 
Schizophrenia is thought to have a high heritability of between 64- 81% [1-3] but the 
exact nature of this genetic risk is complex and few of the many targeted research 
studies have led to significant reproducible genetic associations with schizophrenia.  
Evidence suggests that the complexity of schizophrenia inheritance is a result of the 
involvement of multiple loci that act both additively and epistatically [4].  Adding to 
this is the possibility that environmental factors also interact with certain genotypes. 
 
To date, a number of polymorphisms have been identified that are associated with 
schizophrenia.  Many of these are associated with the dopamine pathway in the brain 
and are likely to cause over-stimulation of dopamine receptors.  Hence the primary 
site of action of anti-psychotic medication is dopamine receptors.  The glutamatergic 
pathway has also been proposed to modulate the pathogenesis of schizophrenia.  The 
first metabotropic glutamate 2/3 (mGlu2/3) receptor agonistic drug was based on the 
glutamatergic hypothesis [5] and is the first drug developed not acting as a dopamine 
antagonist.  This hypothesis is based on glutamate hypofunction which ultimately 
leads to increased sensory flooding and changes in dopamine concentration.  
Dystrobrevin binding protein 1 (DTNBP1), otherwise known as dysbindin, is one of 
the genes thought to be pivotal in regulating the glutamatergic system. 
 
Through linkage and association studies DTNBP1 has been extensively investigated 
but there is conflicting evidence for association with schizophrenia.  A meta-analysis 
identified only a weak association of one DTNBP1 SNP with schizophrenia, which 
was not significant after multiple testing [6].  DTNBP1 was first associated with 
schizophrenia when linkage studies identified 6p24-p22 as a region of high 
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schizophrenia susceptibility [7-9].  Later investigations reported associations in Irish 
pedigrees with eight DTNBP1 single nucleotide polymorphisms (SNPs) [8].  
Associations with six of these polymorphisms were replicated in sib-pair and triad 
families [10].  Differences were observed in a Chinese population but analysis of the 
6p22.3 region still showed strong association with schizophrenia [11].  Associations 
have also been identified in Caucasian and Hispanic populations [12].  Since these 
earlier studies several haplotypes have been identified to be associated with 
schizophrenia, although no common polymorphism or haplotype has been established 
[13-22].  There are also a number of studies that failed to identify an association 
between DTNBP1 and schizophrenia [15,23-27]. 
 
The 140 kilobase DTNBP1 gene contains eight exons and encodes a 40 kDa neuronal 
protein dystrobrevin binding protein 1 that binds to alpha- and beta-dystrobrevin in 
muscle and brain [28].  It is found highly concentrated in mossy fibre synaptic 
terminals in both the cerebellum and hippocampus [28,29] and functional studies have 
also implicated it in schizophrenia pathogenesis [16,30-33].  A role has been 
hypothesised in cognitive functioning and memory as well as maintaining 
glutamatergic neurotransmission [34].  Studies have found widespread DTNBP1 
mRNA in the brain, reduced mRNA expression in dorsolateral prefrontal cortex and 
hippocampal formation [33] and reduced protein expression of hippocampal 
formation in schizophrenia patients [29,32].  Reduced DTNBP1 mRNA expression in 
cerebral cortex has also been associated with risk haplotypes for schizophrenia [30]. 
 
Association and functional studies suggest a role for DTNBP1 in schizophrenia and 
dysbindin deficient mice have been shown to provide a good model for schizophrenia 
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[35-39].  To identify novel polymorphism associations and confirm previous 
association studies, 13 SNPs in DTNBP1 that span from the 3'-end to the 5'-end of the 
gene were selected to mark the haplotype blocks in DTNBP1 so that all associations 
could be detected.  These 13 SNPs were then genotyped to investigate possible 
genetic association with schizophrenia. 
 6
2.  Materials and Methods 
2.1  Subjects 
The study included 160 schizophrenia patients and 250 unrelated Caucasian controls.  
Subjects were aged between 18 and 65 years.  Diagnostic and Statistical Manual of 
Mental Disorders-IV (DSM-IV) diagnosis of schizophrenia was confirmed by at least 
two independent psychiatrists.  These patients had never been diagnosed with other 
psychiatric disorders, including schizoaffective disorder, major depressive episode 
with psychotic features, or bipolar disorder.  No patients were treated with 
antidepressants, anxiolytic agents, or mood-stabilizing psychotropic medications and 
all were maintained on a constant dose of antipsychotic medication for a minimum of 
three weeks.  There were 22 females and 138 males in the group diagnosed with 
schizophrenia with a mean age of 36.2 years (s.d. + 12.1 years).  The mean age of 
patients at first diagnosis was 23.4 years (s.d. + 7.47 years).  They were being treated 
at the Royal Brisbane and Women's Hospital, The Park Psychiatric Unit, and the 
Valley Community Psychiatric Centre.  The clinical sample was composed of 69 
inpatients and 91 outpatients. All patients were administered the Positive and 
Negative Symptom Scale (PANSS) [40] to assess severity of psychotic features.  A 
history of psychological distress, indicated by past suicidal behaviour, was reported 
by 74 patients.  A total of 121 patients were able to provide information on psychiatric 
illness among first-degree relatives and 82 of these patients (68%) reported a positive 
family history of schizophrenia.  This clinical sample was a group who had lived with 
schizophrenia for an average of 13 years since diagnosis continued to experience 
positive and negative symptoms despite treatment with antipsychotic medication.  In 
addition the group contained a significant proportion of individuals with a relatively 
severe history and/or a familial risk for psychosis. 
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The control group consisted of 102 females and 148 males, with a mean age of 36.8 
years (s.d. + 12.8 years).  The control group consisted mostly of medical and nursing 
staff recruited through hospitals, and university students and academic staff.  Formal 
screening for schizophrenia or other psychological disorders was not undertaken in 
the control population.  As such, the controls represent an unselected control group. 
 
Ethics approval was obtained from all institutions involved. 
 
2.2  Selection of SNPs 
Using the International HapMap Project (HapMap) phase II [41], eleven tag-SNPs in 
DTNBP1 with a minor allele frequency of 0.15 were selected.  Tag-SNPs were 
identified using the pair-wise option of Tagger with a threshold of r2 > 0.8.  Two non-
synonymous SNPs reported in The National Center for Biotechnology Information 
(NCBI) SNP database (dbSNP) were also chosen. 
 
2.3  Genotyping 
Oragene kits were used to extract DNA from saliva samples.  Samples were 
genotyped using a homogeneous MassEXTEND (hME) Sequenom assay performed 
by the Australian Genome Research Facility.  The hME assay is based on the 
annealing of an oligonucleotide primer (hME primer) adjacent to the SNP of interest. 
The addition of a DNA polymerase along with a mixture of terminator nucleotides 
allows extension of the hME primer through the polymorphic site and generates 
allele-specific extension products, each having a unique molecular mass. The resultant 
masses of the extension products are then analysed by matrix-assisted laser 
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desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS) and a 
genotype is assigned in real time. The hME assay was performed in multiplex with up 
to 36 reactions in a single well. 
 
2.4  Statistical Analysis 
A Pearson’s chi-squared test was performed to identify statistical associations 
between alleles/genotype and schizophrenia status.  Odds ratios (OR) were also 
calculated.  Tests were performed on both genotype and allele data.  All statistical 
tests were performed using the COMPARE2 program from the WinPepi suite of 
epidemiology programs [42].  Hardy-Weinberg equilibrium (HWE) was computed 
using Utility Programs for Analysis of Genetic Linkage [43].  The analysis of 
genotypes under a recessive model involved pooling the low-risk homozygotes and 
the heterozygotes and comparing frequencies with the high-risk homozygotes, i.e. OR 
> 1.  Correction for multiple testing was conducted using the Benjamini-Hochberg 
method [44]. 
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3.  Results 
A comprehensive genotype analysis of DTNBP1 and its association with 
schizophrenia was undertaken using a haplotype block-based gene-tagging approach.  
A total of eleven tag-SNPs and two non-synonymous SNPs from NCBI that span 
from the 3'-end to the 5'-end of the gene were genotyped in a sample of 160 
schizophrenia patients and 250 controls.  One of the non-synonymous SNPs, 
rs16876589, was excluded from the final analysis after genotyping revealed no 
heterogeneity.  Three of the remaining 12 SNPs analysed were found to be 
significantly (p <0.05) associated with schizophrenia at the allele level (Table 1) and a 
further two SNPs were approaching significance.  These included four tag-SNPs; 
rs1997679, rs9370823, rs9370822, rs4236167 and one non-synonymous SNP 
identified in NCBI, rs17470454 (Table 1).  All of these SNPs were selected for further 
analysis at the genotype level (Table 2).  Genotype frequencies indicated that all 
polymorphisms were in HWE in both case and control samples, with the exception of 
rs17470454 which was not in HWE for either group.  Data from this SNP was 
therefore excluded from further analyses.  One of the tag-SNPs (rs4236167) was 
significant at the genotype (p = 0.03) but not at the allele level.  The rs1997679 SNP 
achieved significance at the genotype level when it was analysed using the Mantel-
Haenszel test for trend but only rs9370822 was significant at both the allele (p = 
0.002) and genotype (p = 0.004) level and it was the only SNP to survive correction 
for multiple testing (corrected α-values varied between 0.025 to 0.0125, for the two 
nominally significant SNPs) . 
 
When compared to the low-risk homozygote, the odds ratios of the other two 
genotypes indicated that a recessive pattern of inheritance for schizophrenia 
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susceptibility was present for all 4 remaining SNPs, i.e. both the heterozygote OR and 
the OR for the low-risk homozygote were approximately one (Table 2).  All four 
SNPs were subsequently found to be associated with schizophrenia when analysed 
under a recessive model by pooling genotypes (Table 3); again, rs9370822 showed 
the strongest association under a recessive inheritance model.  All four associations 
survived correction for multiple testing (corrected α-values varied between 0.05 and 
0.0125, for the four nominally significant SNPs). 
 
In order to evaluate whether there was any sexual dimorphism in the population, the 
male schizophrenia patients were analysed separately from the female patients.  At the 
allele level, the same four SNPs showed association with disease with slightly 
improved p-values (rs9370822, p = 0.0006; rs4236167, p = 0.017; rs1997679, p = 
0.023; rs9370823, p = 0.036) although only rs9370822 survived correction for 
multiple testing.  At the genotype level, the same four SNPs were even more clearly 
associated with schizophrenia when genotypes were analysed independently or under 
a recessive model (recessive model p-values: rs9370822, p = 0.0005; rs4236167, p = 
0.002; rs1997679, p = 0.006; rs9370823, p = 0.009).  The remaining female cases 
were too small in number to analyse meaningfully. 
 
4.  Discussion 
Analysis of eleven tag-SNPs and two non-synonymous SNPs in DTNBP1 revealed 
associations with schizophrenia at the allele or genotype level for four DNTBP1 
polymorphisms (rs1997679, rs9370823, rs9370822 and rs4236167) in an Australian 
schizophrenia cohort.  The rs1997679, rs9370823 and rs4236167 SNPs have been 
analysed previously but were not found to be associated with schizophrenia 
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[24,26,27,45].  The strongest association was found for the rs9370822 SNP which has 
not previously been tested by other groups.  Of the remaining nine SNPs studied in 
this paper, rs2743857 and rs16876589 have not previously been studied while the 
remaining seven SNPs have been analysed for association with schizophrenia but did 
not show association [19,21,24,25,27,45-47]. 
 
Although rs9370822 has not been analysed previously by other groups, Duan et al. 
[48] identified three other SNPs (rs875462, rs760666 and rs7758659), all located in 
intron seven and flanking rs9370822 that were significantly associated with 
schizophrenia.  We analysed rs7758659 in our study but we observed no association 
with schizophrenia (allele association p = 0.91). 
 
In 2006, Mutsuddi et al. [49] analysed data from six earlier studies that reported 
association of DTNBP1 with schizophrenia but they found no consistency between the 
reported associations with schizophrenia.  None of the SNPs reported in our study 
were analysed by Mutsuddi et al. [49].  A recent case-control study of twelve 
DTNBP1 SNPs found one SNP in intron seven (rs1040410) associated with 
schizophrenia and an associated haplotype involving this SNP and two flanking SNPs 
in intron seven (rs875462 and rs6926401) [50], further supporting our observation of 
a strongly associated SNP in intron seven of DTNBP1.  Another recent study failed to 
find schizophrenia association with 39 individual tag-SNPs (including rs9476886, 
rs1997679 and rs3829893) or haplotypes [46].  They did not find rs1997679 to be 
associated with schizophrenia under any inheritance model although it was showing 
indications of nominal association with schizophrenia under a partial dominance 
model.  However, we identified a nominally significant association of the rs1997679 
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SNP with schizophrenia in our cases although the effect was relatively small and 
could have occurred by chance.  We found the SNP to be significant under a T-
dominant/C-recessive (p = 0.019) and partially-dominant (p = 0.048) or additive 
model.   
 
In a very large study of genetic association with schizophrenia, Sanders et al. [27] 
examined SNPs in 14 candidate genes, including DTNBP1, but they did not identify 
any association.  Interestingly, none of these recent studies analysed rs9370822 which 
we found to be the most strongly associated with schizophrenia.  We found rs9370822 
to be significantly associated at both the allele and genotype level and under a T-
dominant/C-recessive model.  Further support for this being a biologically significant 
SNP comes from our observation of weaker association displayed by the two flanking 
SNPs (rs9370823 and rs4236167; Tables 2 and 3) that lie just 6 kb and 11 kb away 
from rs9370822, respectively and the observations by Duan et al. [48] and Vilella et 
al. [50] of association with SNPs that flank rs9370822 .  At this stage it is uncertain 
whether this SNP is in linkage disequilibrium with another functional SNP.  Even 
though this is an intronic SNP if it is in disequilibrium with another SNP it is likely to 
also be in intron 7 as both the flanking SNPs are also in intron 7.  As such, it is 
possible that the functional SNP either affects RNA splicing or gene transcription as 
no coding or untranslated regions are involved. 
 
Another SNP in the 3′-untranslated region of DTNBP1 that looked promising as a 
candidate for schizophrenia etiology was rs1047631.  A study found the A allele to be 
associated with reduced DTNBP1 mRNA expression in the brains of schizophrenic 
patients [30].  This result is consistent with a previous study that found the G allele 
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was associated with an increase in mRNA levels in the pre-frontal cortex of 
schizophrenia brains [33].  Bray et al. [30] also found the A-allele to be included in a 
schizophrenia risk haplotype.  However, we found no significant association with the 
rs1047631 SNP and schizophrenia. 
 
Examination of the odds ratios for the genotypes of all associated SNPs in our study 
suggests that they follow a recessive pattern of inheritance with respect to 
schizophrenia risk (Table 2).  We describe the pattern as recessive because the odds 
ratio of the heterozygote did not differ from the odds ratio of the homozygote for the 
allele that was not associated with schizophrenia.  This is consistent with a DTNBP1 
functional allele that results in loss or reduction of gene function.  It is also consistent 
with the glutamatergic hypothesis [5] which is based on glutamate hypofunction and 
with the observation of recessive inheritance of the dysbindin-1 gene deletion in the 
mouse model of schizophrenia [35].  Interestingly, there is another potential 
mechanism of action of DTNBP1 in schizophrenia that also involves loss-of-function 
or down regulation of DTNBP1.  It has been shown that damping of DTNBP1 
expression with interfering RNA led to an increase in cell surface DRD2 receptors 
[51] which is consistent with an over activity of the dopamine pathway in 
schizophrenia. 
 
Gender differences were also examined in this study as there was an 
underrepresentation of women in our schizophrenia population.  By analysing males 
separately the same four SNPS were still found to be significantly associated with 
schizophrenia.  However, the p-values were improved, indicating possible sexual 
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dimorphism.  Future studies representing a larger female schizophrenia population 
may explain these gender differences.   
 
5.  Conclusions 
This study does not rule out population stratification and therefore our results need to 
be confirmed independently in a Caucasian group as well as defined ethnic groups.  
Population stratification can produce false positive associations where the underlying 
structure of the population results in genetic differences in the frequency of variants 
rather than differences due to the presence of disease susceptibility alleles.   The 
sample size for the schizophrenia population was relatively small and the associations 
await replication preferably using a larger sample of schizophrenia patients or 
possibly other disease cohorts with a similar disease etiology.  However a p-value of 
0.002 for the rs9370822 SNP is encouraging using unselected controls as a more 
significant association is likely to be found using controls screened for lack of a 
mental illness. 
 
To date, no functional variants of DTNBP1 have been identified that are associated 
with schizophrenia.  From our study we identified four SNPs that showed some 
association with schizophrenia.  The strongest association with schizophrenia was 
found with the rs9370822 polymorphism.  Though it is intronic, this SNP may still be 
functional or in disequilibrium with a nearby functional SNP that would also most 
likely be intronic.   
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Table 1 
Allele association of 13 DTNBP1 SNPs with schizophrenia 
 
* Nucleotide position on the chromosome 6 reference sequence 
† p-value determined by Pearson’s chi-squared test 
 
 
SNP ID Position* SNP details χ2 p-value† Odds Ratio  95% CI 
rs9476886 15769440 Intron 1 C/T 0.18 0.894 0.98 0.72-1.34 
rs1997679 15766884 Intron 1 C/T 3.907 0.048 1.37 1.00-1.87 
rs2743857 15758475 Intron 3 A/G 0.121 0.728 0.93 0.63-1.38 
rs3829893 15723616 Intron 5 A/G 0.618 0.432 0.86 0.60-1.25 
rs7758659 15701219 Intron 7 C/T 0.013 0.91 1.02 0.72-1.44 
rs9370823 15658637 Intron 7 A/G 3.729 0.053 1.38 1.00-1.92 
rs9370822 15652715 Intron 7 A/C 9.883 0.002 1.61 1.19-2.17 
rs4236167 15641930 Intron 7 G/T 3.111 0.078 1.30 0.97-1.73 
rs16876589 15641476 Exon 8 D214G Not polymorphic in this study 
rs4712253 15634396 Intron 8 C/T 0.008 0.928 0.99 0.74-1.32 
rs742106 15632459 Intron 9 C/T 0.04 0.841 1.03 0.76-1.40 
rs17470454 15631427 Exon 10 S272P 5.74 0.017 2.03 1.13-3.67 
rs1047631 15631080 3'-UTR A/G 2.386 0.122 0.73 0.48-1.09 
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Table 2 
Genotype association of 5 candidate DTNBP1 SNPs with schizophrenia. 
Polymorphism Genotype counts (%) p-value* 
rs1997679 TT CT CC  
Control 25 (10.8) 111 (47.8) 96 (41.4)    0.060  
   0.048† schizophrenia 15 (9.4) 59 (37.1) 85 (53.5) 
Odds Ratio‡ 
   (p-value) 
1.00 
 
0.89 
(1.00) 
1.48 
(0.55)  
rs9370823 AA AG GG  
Control 124 (56.9) 84 (38.5) 10 (4.6)    0.057 
   0.055† schizophrenia 78 (50.6) 59 (38.3) 17 (11.0) 
Odds Ratio‡ 
   (p-value) 
1.00 
 
1.12 
(1.00) 
2.70 
(0.03)  
rs9370822 AA AC CC  
Control 113 (47.9) 101 (42.8) 22 (9.3)    0.004 
   0.002† schizophrenia 58 (37.2) 66 (42.3) 32 (20.5) 
Odds Ratio‡ 
   (p-value) 
1.00 
 
1.27 
(0.57) 
2.83 
(0.002)  
rs4236167 CC CT TT  
Control 77 (32.4) 124 (52.1) 37 (15.5)    0.032 
   0.080† schizophrenia 46 (30.3) 66 (43.4) 40 (26.3) 
Odds Ratio‡ 
   (p-value) 
1.00 
 
0.89 
(1.00) 
1.81 
(0.09)  
* p-value determined by Pearson’s χ2 test 
† p-value determined using the extended Mantel-Haenszel test for trend 
‡ OR, with respect to the genotype that was not associated with schizophrenia 
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Table 3 
Genotype association of 5 candidate DTNBP1 SNPs with schizophrenia under a 
recessive inheritance model. 
Polymorphism Genotype counts (%) Odds Ratio (95% CI) p-value* 
rs1997679 TT/CT CC   
control 136 (58.6) 96 (41.4) 1.63 
(1.06-2.49) 0.019 schizophrenia 74 (46.5) 85 (53.5) 
rs9370823 AA/AG GG   
Control 208 (95.4) 10 (4.6) 2.58 
(1.08-6.49) 0.018 schizophrenia 137 (89.0) 17 (11.0) 
rs9370822 AA/AC CC   
control 214 (90.7) 22 (9.3) 2.51 
(1.34-4.74) 0.002 schizophrenia 124 (79.5) 32 (20.5) 
rs4236167 CC/CT TT   
control 201 (84.5) 37 (15.5) 1.94 
(1.14-3.31) 0.009 schizophrenia 112 (73.7) 40 (26.3) 
* p-value determined by Pearson’s χ2 test 
DTNBP1 
